Company Willow Biosciences Inc. Canadian Securities Exchange
Equities
WLLW
CA97111B4047
Pharmaceuticals
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
- CAD | -.--% | -.--% | -.--% |
Business Summary
Sales per Business
CAD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Research and Development
100.0
%
| 1 | 77.2 % | 1 | 100.0 % | +84.86% |
Sales per region
CAD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
100.0
%
| 1 | 77.2 % | 1 | 100.0 % | +84.86% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Chris Savile
CEO | Chief Executive Officer | - | 19-04-11 |
Travis Doupe
DFI | Director of Finance/CFO | - | 19-04-11 |
Trish Choudhary
CTO | Chief Tech/Sci/R&D Officer | - | 19-03-31 |
Simon Hickling
PRN | Corporate Officer/Principal | - | - |
Sony Gill
SEC | Corporate Secretary | 48 | 19-04-11 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Jim Lalonde
CHM | Chairman | 63 | 23-02-20 |
Donald Archibald
BRD | Director/Board Member | 63 | 19-04-11 |
Director/Board Member | 51 | 19-04-11 | |
Raffi Asadorian
BRD | Director/Board Member | 54 | 23-05-10 |
Chris Savile
CEO | Chief Executive Officer | - | 19-04-11 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 127,222,030 | 92,512,715 ( 72.72 %) | 0 | 72.72 % |
Company contact information
Willow Biosciences, Inc.
1201 5th Street South West Suite 202
T2R 0Y6, Calgary
+
http://www.willowbio.comSector
Sales per Business
Sales per region
1st Jan change | Capi. | |
---|---|---|
+2.58% | 92.38B | |
-3.16% | 37.9B | |
-12.49% | 33.73B | |
+73.89% | 27.98B | |
-11.82% | 15.86B | |
-0.16% | 13.97B | |
-11.18% | 11.67B | |
+171.57% | 10.17B | |
-50.45% | 10.04B |
- Stock Market
- Equities
- WLLW Stock
- WLLW Stock
- Company Willow Biosciences Inc.